Apollomics Liabilities And Stockholders Equity from 2010 to 2024

APLM Stock   11.25  0.00  0.00%   
Apollomics Liabilities And Stockholders Equity yearly trend continues to be very stable with very little volatility. Liabilities And Stockholders Equity is likely to grow to about 85 M this year. Liabilities And Stockholders Equity is the total of all liabilities and equity in the company, which should equal Apollomics' total assets according to the accounting equation. View All Fundamentals
 
Liabilities And Stockholders Equity  
First Reported
2010-12-31
Previous Quarter
55.4 M
Current Value
85 M
Quarterly Volatility
41 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Apollomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apollomics' main balance sheet or income statement drivers, such as Tax Provision of 10.5 K, Net Interest Income of 633.1 K or Interest Income of 544.8 K, as well as many indicators such as Price To Sales Ratio of 8.3 K, Dividend Yield of 0.0 or PTB Ratio of 183. Apollomics financial statements analysis is a perfect complement when working with Apollomics Valuation or Volatility modules.
  
Check out the analysis of Apollomics Correlation against competitors.

Latest Apollomics' Liabilities And Stockholders Equity Growth Pattern

Below is the plot of the Liabilities And Stockholders Equity of Apollomics Class A over the last few years. It is the total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation. Apollomics' Liabilities And Stockholders Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apollomics' overall financial position and show how it may be relating to other accounts over time.
Liabilities And Stockholders Equity10 Years Trend
Slightly volatile
   Liabilities And Stockholders Equity   
       Timeline  

Apollomics Liabilities And Stockholders Equity Regression Statistics

Arithmetic Mean147,313,200
Geometric Mean139,772,300
Coefficient Of Variation27.84
Mean Deviation33,187,440
Median169,941,000
Standard Deviation41,011,928
Sample Variance1682T
Range114.6M
R-Value(0.75)
Mean Square Error782.8T
R-Squared0.57
Significance0
Slope(6,910,432)
Total Sum of Squares23547.7T

Apollomics Liabilities And Stockholders Equity History

202485 M
202355.4 M
202276.5 M
2021123.4 M

About Apollomics Financial Statements

Apollomics investors utilize fundamental indicators, such as Liabilities And Stockholders Equity, to predict how Apollomics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Liabilities And Stockholders Equity55.4 M85 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Apollomics Class A is a strong investment it is important to analyze Apollomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apollomics' future performance. For an informed investment choice regarding Apollomics Stock, refer to the following important reports:
Check out the analysis of Apollomics Correlation against competitors.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.15)
Revenue Per Share
0.023
Quarterly Revenue Growth
2.623
Return On Assets
(0.63)
Return On Equity
(1.49)
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apollomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.